Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (31-40 of 1,279) with videos related to

Pageof 128
Sort By:
Future Oncology (London, England)|February 7, 2024
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice?Michele Maffezzoli, Sebastiano Buti
Clinical Liver Disease|July 2, 2024
HBV elimination in Europe: Current status and challengesMaria Buti, Erika Duffell
Future Oncology (London, England)|May 12, 2016
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trialsSebastiano Buti, Melissa Bersanelli
World Journal of Clinical Oncology|March 2, 2017
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axisMelissa Bersanelli, Sebastiano Buti
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 5, 2013
Preparing the patient for success: treat or wait?Maria Buti, Rafael Esteban
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 26, 2024
Towards eliminating hepatitis C as a public health threat: different speeds, different needsMojca Matičič, Maria Buti
Expert Review of Gastroenterology & Hepatology|September 16, 2014
Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'Maria Buti, Rafael Esteban
Medicina Clinica|December 5, 1987
[Diagnosis and treatment of idiopathic hemochromatosis]M Buti, R Esteban
The Lancet. Oncology|October 21, 2015
Combination therapy in kidney cancer: the next revolution?Sebastiano Buti, Melissa Bersanelli
Drugs of Today (Barcelona, Spain : 1998)|April 17, 2003
Adefovir dipivoxilMaría Buti, Rafael Esteban
Pageof 128

Showing results (31-40 of 1,279) with videos related to

Sort By:
Pageof 128
Future Oncology (London, England)|February 7, 2024
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice?Michele Maffezzoli, Sebastiano Buti
Clinical Liver Disease|July 2, 2024
HBV elimination in Europe: Current status and challengesMaria Buti, Erika Duffell
Future Oncology (London, England)|May 12, 2016
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trialsSebastiano Buti, Melissa Bersanelli
World Journal of Clinical Oncology|March 2, 2017
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axisMelissa Bersanelli, Sebastiano Buti
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 5, 2013
Preparing the patient for success: treat or wait?Maria Buti, Rafael Esteban
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 26, 2024
Towards eliminating hepatitis C as a public health threat: different speeds, different needsMojca Matičič, Maria Buti
Expert Review of Gastroenterology & Hepatology|September 16, 2014
Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'Maria Buti, Rafael Esteban
Medicina Clinica|December 5, 1987
[Diagnosis and treatment of idiopathic hemochromatosis]M Buti, R Esteban
The Lancet. Oncology|October 21, 2015
Combination therapy in kidney cancer: the next revolution?Sebastiano Buti, Melissa Bersanelli
Drugs of Today (Barcelona, Spain : 1998)|April 17, 2003
Adefovir dipivoxilMaría Buti, Rafael Esteban
Pageof 128